2025-12-07 - Analysis Report
Okay, here's a breakdown of the Hims & Hers Health Inc. (HIMS) data, with analysis and comparison to the S&P 500 (VOO):

**1) Return Rate Comparison**

*   **Ticker:** HIMS
*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company offering personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 139.33%
*   **VOO Cumulative Return:** 75.23%
*   **Divergence:** 82.8
*   **Relative Divergence:** 41.4

**Analysis:**

*   HIMS has significantly outperformed the S&P 500 (VOO) in terms of cumulative return.
*   The divergence of 82.8 indicates the absolute difference in cumulative returns between HIMS and VOO.
*   The relative divergence of 41.4 suggests that the current divergence is in the lower-middle range of its historical fluctuations (between the minimum and maximum divergence values).

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2019-2021  | -42.0% | 74.4% | -81.0% | 0.0   | 1.6    |
| 2020-2022  | -19.0% | 78.6% | -18.0% | -0.0  | 1.5    |
| 2021-2023  | -65.0% | 78.6% | -67.0% | -0.1  | 2.1    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0  | 5.8    |
| 2023-2025  | 144.0% | 80.8% | 78.0%  | 0.1   | 8.9    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows a wide range of performance, from significant losses (e.g., -65.0% in 2021-2023) to substantial gains (e.g., 144.0% in 2023-2025). This indicates high volatility.
*   **MDD:** Maximum Drawdown is consistently high, around 74-81%, signifying significant risk.
*   **Alpha:**  Alpha, which measures performance relative to a benchmark, is largely negative in the earlier periods, but significantly positive recently (98.0% and 78.0%).  This suggests HIMS has recently been generating returns independent of market movements.
*   **Beta:** Beta values are close to 0, which is unusual. A beta of close to zero suggests that HIMS's price is uncorrelated to the market benchmark (S&P 500).
*   **Cap(B):** Market capitalization has grown from 1.6B to 8.9B.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** $37.07
*   **Last Market Data:** Price $39.2, Previous Close $40.02, Change -$2.05
*   **5-day SMA:** $37.68
*   **20-day SMA:** $37.92
*   **60-day SMA:** $47.81

**Analysis:**

*   The stock price is below all three Simple Moving Averages (SMAs), especially the 60-day SMA. This suggests a recent downtrend.
*   The last market data shows the price went down.

**3) Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 45.21
*   **PPO:** 1.13
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 7.5% (Positive)
*   **Expected Return (%):** 18.1%

**Analysis:**

*   **MRI:** Indicates a medium level of risk, suggesting moderate investment potential.
*   **RSI:** The RSI of 45.21 is neutral, not indicating overbought or oversold conditions.
*   **PPO:** The Positive Percentage Oscillator (PPO) is positive (1.13), suggesting a slightly bullish trend.
*   **Hybrid Signal:** It suggests the stock is in a very safe area and that a good purchase could be made.
*   **Recent Divergence Change:** The positive divergence change suggests a short-term upward trend.
*   **Expected Return:** The expected return of 18.1% is attractive if the investment horizon is long-term.

**4) Recent News & Significant Events**

*   **$250 Million Share Repurchase Program:** Positive signal, indicating confidence in the company's financial position and potential to boost share value.
*   **15.6% Plunge in 3 Months:** Negative signal, suggests recent underperformance and potential concerns among investors.
*   **Secret Biotech Bet Exploding:** Positive signal, indicating diversification and growth in other areas.
*   **Buyout Deal Boosts Blood Collection Efficiency:** Positive signal, indicates that the company made an innovative investment.
*   **Moves to Bolster Obesity Biz:** Positive, focusing on growth.
*    **Clear Street LLC Invests $83.58 Million:** Positive, indicates confidence from institutional investors.

**Analysis:**

The news is mixed. The share repurchase program, biotech growth, obesity focus, and institutional investment are positive. However, the recent price plunge is a concern.

**4-2) Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 3.00 (Hold)
*   **Number of Opinions:** 11
*   **Target Price (avg/high/low):** $44.36 / $85.00 / $25.00
*   **Recent Rating Changes:** No changes

**Analysis:**

The analyst consensus is a "Hold" with a mean rating reflecting this. The average target price suggests moderate upside potential from the current price.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-11-03 | 0.07 | 0.60 B$    |
| 2025-08-04 | 0.19 | 0.54 B$    |
| 2025-05-05 | 0.22 | 0.59 B$    |
| 2024-11-04 | 0.35 | 0.40 B$    |
| 2025-11-03 | 0.35 | 0.40 B$    |

**Analysis:**

Revenue has grown significantly over the past year. EPS has declined.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.60B   | 73.80%        |
| 2025-06-30 | $0.54B   | 76.39%        |
| 2025-03-31 | $0.59B   | 73.50%        |
| 2024-12-31 | $0.48B   | 76.81%        |
| 2024-09-30 | $0.40B   | 79.16%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE   |
|------------|----------|-------|
| 2025-09-30 | $0.58B   | 2.72% |
| 2025-06-30 | $0.56B   | 7.55% |
| 2025-03-31 | $0.55B   | 9.01% |
| 2024-12-31 | $0.48B   | 5.46% |
| 2024-09-30 | $0.44B   | 17.18% |

**Analysis:**

*   **Revenue:** Shows consistent growth over the quarters.
*   **Profit Margin:** Generally strong and relatively stable.
*   **Equity:** Increasing, indicating growth in the company's net assets.
*   **ROE:** Return on Equity is highly variable and recently decreased.

**7) Comprehensive Analysis (Summary)**

*   **Performance:** HIMS has significantly outperformed the S&P 500, but has experienced high volatility.
*   **Technicals:** Recent price action is weak, with the price below key moving averages. The RSI is neutral. The hybrid signal is very safe.
*   **News:** Mixed news flow, with positive developments offset by a recent price plunge.
*   **Analyst Opinion:** Neutral (Hold).
*   **Earnings:** Revenue growth is positive, but EPS has decreased.
*   **Financials:** Strong revenue growth and profit margins, but ROE is decreasing.

**Overall:**

HIMS presents a mixed picture. The company has strong growth potential and has outperformed the market significantly in the past. However, there are concerns about recent price weakness, declining profitability (EPS and ROE), and high volatility. The analyst consensus is neutral. The recent drop is a concern, and you need to understand the risk of high price fluctuation.

**Recommendation:**

Given the mixed signals, a cautious approach is warranted. Further research is recommended to understand the reasons behind the recent price decline and the trends in profitability (EPS and ROE).



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.